Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 14Breast 7Myeloid 6Thoracic 5Gynecologic 3Genitourinary 3Dermatologic 3Classical hematology 3Plasma cell 2Head & Neck 2CNS 2Tumor-Agnostic 1Other neoplasm 1Other hematologic neoplasm 1

Conditions

Melanoma 3

Interventions

Nivolumab 114Ipilimumab 114pembrolizumab 108aldesleukin 76Cyclophosphamide 70fludarabine phosphate 51Interleukin-2 48Temozolomide 41Dacarbazine 36trametinib 33dabrafenib 30Bevacizumab 30sargramostim 29Radiotherapy 29incomplete Freund's adjuvant 27fludarabine 27Vemurafenib 25Radiosurgery 25Carboplatin 25Paclitaxel 23binimetinib 22Biopsy 22CTLA-4 Antigen 21Peripheral Blood Stem Cell Transplantation 20encorafenib 19cemiplimab 19atezolizumab 19Mycophenolic Acid 19HhAntag691 19Aminolevulinic Acid 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Aspirin × Dermatologic × Clear all
NCT03396952 2022-10-13

Prostaglandin Inhibition and Immune Checkpoint Blockade in Melanoma

University of California, San Francisco

Phase 2 Completed
27 enrolled 13 charts
Dermatologic

Melanoma

NCT04062032 2022-02-18

Metabolomic and Inflammatory Effects of Oral Aspirin (ASA) in Subjects at Risk for Melanoma

University of Utah

Phase 2 Completed
41 enrolled
Dermatologic

Melanoma

NCT04066725 2022-02-18

Aspirin as an Ultraviolet (UV) Protectant in Human Subjects at Risk for Melanoma

University of Utah

Phase 2 Completed
95 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡